Three Case Western Reserve University researchers have been awarded funds to develop new technologies for several conditions, including cystic fibrosis.
A research team at Stanford University has developed a blood test designed to screen newborns for all types of cystic fibrosis.
The US Food and Drug Administration has denied the expanded use of Kalydeco in cystic fibrosis patients ages 2 or older who have one of 23 residual function mutations.
The Mayo Clinic has partnered with CysticLife.org, a social network for the cystic fibrosis community, to conduct a large cystic fibrosis exercise study.
UNC researchers suggest new targets for cystic fibrosis (CF) therapy and support the case for inflammation as an acquired response unrelated to the CFTR genetic mutation.
The oral cystic fibrosis drug ivacaftor (Kalydeco) was well tolerated in preschool-age children with cystic fibrosis who had CFTR gating mutations.
A new study finds that the incidence of rejection in lung transplant patients is high among individuals with cystic fibrosis.
The FDA has granted orphan drug designation to Nivalis Therapeutics Inc's N91115 for the treatment of patients suffering from cystic fibrosis.
AiCure has raised $12.25 million for its novel medication adherence platform that uses smartphones to monitor a patient's usage.
Researchers at The University of Nottingham (UK) are investigating whether a new type of hearing test could successfully detect early hearing loss in people with cystic fibrosis.
A new study has revealed that different combinations of cis-regulatory elements contribute to the chromatin structure of the CFTR gene and to the gene’s varying expression in tissue, according to Lung Disease News.
Variants examined in the most common CF newborn screening panels do not sufficiently include the variants present in nonwhite populations.
RT has published an exclusive tablet-only “Best of 2015” edition for December that takes a look back at some of the year’s most important respiratory, critical care, and emergency medicine news and research.
A review of airway clearance therapies for CF patients showed that patients using positive expiratory pressure (PEP) devices reported lower exacerbation rates when compared to other techniques.
Nivalis Therapeutics has announced that a clinical study of its investigational drug N91115 for cystic fibrosis has begun treating its first patient.
The majority of mice with CF that were administered a new gene therapy recovered, with chloride and fluid transport restored in patient-derived cell cultures, researchers say.
A new study published in the Journal of Inflammation shows that the cystic fibrosis transmembrane conductance regulator (CFTR) plays an important role in regulating intestinal inflammatory responses.
Concert Pharmaceuticals has announced that it has initiated a clinical trial for its drug candidate CTP-656 for the treatment of cystic fibrosis.
OrPro Therapeutics, Inc, a cystic fibrosis treatment, has received a patent covering the drug’s capacity to improve the viscoelastic properties of mucus secretions.
Researchers have identified a genetic signature due to the inflammatory response in cystic fibrosis human bronchial epithelial cells infected with P. aeruginosa bacterium.